Three years ago, AbbVie’s biggest drug lost its U.S. patent protection and the company braced for a revenue cliff. Humira, the anti-inflammatory medicine that had been the world’s best-selling drug for years, was about to face cheap copies. The question was whether AbbVie had built enough of a replacement engine in time. The answer, reported in the Q2 2026 earnings press release and the 10-Q filed with the SEC for the quarter ended June 30, 2026, is starting to look like yes.
In one breath
The two drugs AbbVie bet its future on, Skyrizi and Rinvoq, are each growing about 24% a year and together now generate more revenue in a single quarter than AbbVie’s entire oncology and aesthetics segments combined. The stock trades near the richest valuation relative to revenue it has seen in a decade. The open question is whether the company’s thin reported profit margins, weighed down by acquisition costs and a $10.9 billion deal still closing, reflect a business in transition or a structural problem that the growth numbers are papering over.
The quarter that settled the debate
AbbVie’s 10-Q for the quarter ended June 30, 2026 reported worldwide net revenues of $17.0 billion, up more than a tenth from the same quarter a year earlier. That single quarter is worth more than AbbVie earned in any single quarter of 2020, a year when the company posted $45.8 billion in full-year revenue. The immunology segment, which houses Skyrizi and Rinvoq, brought in more than half the company’s total revenue and grew at a double-digit pace year over year. Neuroscience, led by the psychiatric drug Vraylar, added another substantial slice, up roughly a fifth. These two segments are now the engine; everything else is ballast.
Skyrizi, which treats skin and bowel conditions, posted $5.5 billion in Q2 2026 sales, a 24% jump from a year earlier. Rinvoq, which treats arthritis and related conditions, matched that pace almost exactly. Together they generated more revenue in one quarter than AbbVie’s entire oncology and aesthetics businesses combined. That concentration is both the story’s strength and its central risk.
What the filing history actually shows
The decade of filings tells a lurching story. FY2023 saw revenue fall as Humira biosimilars, cheaper copycat versions of the drug, hit the U.S. market. Net margins that year fell to roughly nine percent, meaning the company kept about nine cents of each dollar of sales. FY2024 was worse on the bottom line, with reported net income of roughly $4.3 billion, about seven cents of each sales dollar, weighed down by acquisition-related charges from the $63 billion Allergan deal completed in 2020. The FY2025 annual filing showed revenue recovering strongly, but net margins only reached about 7%, still thin for a pharmaceutical company that typically commands margins several times that level. Our data show the price-to-sales ratio sitting at the 92nd percentile of its own decade range, meaning the stock is priced more richly relative to revenue than at almost any point in the past ten years.
The gap between that premium valuation and those slim margins is the tension worth watching. A pharmaceutical company’s reported earnings can be heavily distorted by amortization, the accounting process of spreading the cost of an acquisition across many years. AbbVie paid $63 billion for Allergan; that cost flows through the income statement for years afterward, suppressing reported profit even when the underlying business is healthy. Whether that fully explains the margin picture, or whether there is something more structural, is a question the filings raise but do not cleanly resolve.
The deals piling up
AbbVie has not slowed its acquisition pace. In June 2026, the company agreed to buy Apogee Therapeutics for $10.9 billion, targeting late-stage drugs for atopic dermatitis and asthma, conditions where Skyrizi and Rinvoq do not yet compete. That deal is expected to close in Q3 2026 and will add another layer of amortization charges. Earlier in the year, AbbVie paid $650 million upfront to license RC148, a cancer-targeting antibody from RemeGen, with milestone payments of up to $4.95 billion if the program delivers. A separate pain-drug licensing deal with Haisco Pharmaceutical followed in April. The company is spending aggressively to ensure that no single drug ever again represents the existential concentration risk that Humira did.
Pipeline: the next bets
Reports of positive Phase 3 trial results for Epkinly in a type of aggressive blood cancer, and of a European Commission approval of the same drug for a second blood cancer indication around the same time, have circulated in the market; however, a primary source such as an AbbVie press release or an official EC/EMA announcement has not been independently verified for this article, and readers should treat these claims as unverified pending confirmation from a primary source. A Phase 1 obesity drug, ABBV-295, showed meaningful body weight reduction at twelve weeks in early data announced in March 2026, placing AbbVie in the crowded but enormous weight-loss drug market. Phase 1 data is early, meaning most compounds at this stage never reach patients, so this is a possibility rather than a promise. AbbVie also submitted a regulatory application to expand Skyrizi into a new Crohn’s disease treatment route in April 2026, which, if approved, would widen the drug’s already large addressable market.
Reading the numbers
- $17.0 billion, Q2 2026 net revenue. What it is: total sales for the three months ended June 30, 2026. What it means here: AbbVie is now generating revenue at a pace of roughly $68 billion a year, above its own raised full-year guidance of $67.6 billion. In everyday terms: a business earning at this rate takes in more in a single day than most large hospitals earn in a year.
- 24%, Skyrizi and Rinvoq growth rate. What it is: year-over-year sales increase for each drug in Q2 2026. What it means here: both drugs are growing roughly three times faster than the overall U.S. economy. A household budget growing at 24% a year would double in about three years.
- 6.9%, FY2025 net margin. What it is: the share of each revenue dollar that became profit after all costs, per the FY2025 10-K. What it means here: for every $100 of medicine AbbVie sold last year, it kept about $7. Large pharmaceutical peers often keep $15 to $25. The gap is largely explained by acquisition amortization, but it is still a gap.
- P/S of 7.0, at the 92nd percentile of its own decade. What it is: price-to-sales, meaning what investors currently pay for each dollar of annual revenue, per our data. What it means here: the stock is priced as if the growth story is already proven. At 7 times sales, the arithmetic of valuation compression becomes relevant: if revenue growth were to slow materially, the same multiple applied to lower growth expectations would produce a lower implied valuation, a scenario the filing data allow readers to model.
- $10.9 billion, Apogee acquisition price. What it is: the agreed purchase price for Apogee Therapeutics, announced June 2026. What it means here: this is roughly one-sixth of AbbVie’s entire annual revenue, committed to a company whose drugs have not yet reached market. It is a large bet on a pipeline that does not yet generate a dollar of sales.
For the standing yardsticks on Abbvie: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Abbvie.
Sources
- AbbVie 10-Q, quarter ended June 30, 2026, SEC EDGAR
- AbbVie 10-K, fiscal year ended December 31, 2025, SEC EDGAR
- AbbVie 10-K, fiscal year ended December 31, 2024, SEC EDGAR
- AbbVie 10-K, fiscal year ended December 31, 2023, SEC EDGAR
- AbbVie Q2 2026 earnings press release, PR Newswire, August 3, 2026
- ABBV-295 Phase 1 results, AbbVie newsroom, March 9, 2026
- Apogee Therapeutics acquisition announcement, Quartr
- Skyrizi and Rinvoq growth analysis, TIKR
